Felix Baker will succeed Pierre Legault as chairman of the Bicycle Therapeutics (BCYC) board of directors as Legault and Richard Kender, will retire from the Board following the company’s annual general meeting on June 17. Furthermore, Eric Westin has been promoted to chief medical officer. Prior to joining Bicycle Therapeutics, Westin was vice president of clinical development and translational sciences of ImmunoGen through its acquisition by AbbVie.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Promising Upside for Bicycle Therapeutics: Buy Rating Backed by Positive Clinical Data and Market Potential for ZP Treatment
- Bicycle Therapeutics: Promising Pipeline Progress and Expansion Opportunities Drive Buy Rating
- Bicycle Therapeutics Reports 2024 Progress and Financial Results
- Promising Developments and Strong Financial Position Drive Positive Outlook for Bicycle Therapeutics
- Bicycle Therapeutics: Undervalued Stock with Promising Pipeline and Innovative Platform